Pfizer isn't the only one I actually spoke with the chief scientific officer of Eli Lilly and they said you know with something like messenger RNA it's a technology. You should expect every pharmaceutical company to use that same technology as one of the fundamental pillars of building out a drug business moving forward. But say these things stay separate even like what is that what does that business look like are they is there a conversation about keeping these things separate and maybe that's more lucrative than if they're one.
Bloomberg News Legal Reporter Jef Feeley explains why Elon Musk is reviving his original deal to buy Twitter at the price of $54.20 a share. Bloomberg Balance of Power Anchor David Westin discusses Micron's plan for a $100 billion for semiconductor factory in New York. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Riley Griffin provide the details of Riley's Businessweek Magazine story Pfizer Needs to Prove That It’s Ready to Move On From Covid-19. Stewart Glickman, Head of Energy Research at CFRA, talks about investing in energy firms in this inflationary environment. And we Drive to the Close with Sylvia Jablonski, CEO at Defiance ETFs.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.